题名

非小細胞肺癌之免疫治療

DOI

10.6666/ClinMed.202106_87(6).0061

作者

羅永鴻;邱昭華

关键词

非小細胞肺癌(non-small cell lung cancer) ; 免疫治療(immunotherapy) ; 免疫檢查點抑制劑(immune checkpoint inhibitor)

期刊名称

臨床醫學月刊

卷期/出版年月

87卷6期(2021 / 06 / 25)

页次

367 - 372

内容语文

繁體中文

中文摘要

肺癌是全球癌症患者死亡的主要原因。近10多年來,標靶藥物的發展使非小細胞肺癌的治療效果顯著提升,但對於缺乏致癌驅動基因突變之肺癌而言,標靶治療的成效不佳。然而,近年來蓬勃發展的免疫治療,已經在這類患者族群中展現了顯著的療效,從而提高了存活率與生活品質。一些計畫性細胞死亡蛋白-1(programmed cell death protein 1, PD-1)、計畫性細胞死亡蛋白-1配體(PD-1 ligand, PD-L1)、及細胞毒殺性T淋巴球相關抗原4(cytotoxic T-lymphocyte-associated antigen 4, CTLA-4)單株抗體抑制劑有良好的安全性及療效,已被納入非小細胞肺癌的臨床治療方法。本文主要探討目前現有的免疫療法於局部晚期及晚期非小細胞肺癌之臨床試驗結果及療效,對此類癌症之免疫治療提供綜合性之回顧與分析。

主题分类 醫藥衛生 > 基礎醫學
醫藥衛生 > 社會醫學
参考文献
  1. Ahn, JS,Ahn, YC,Kim, JH(2015).Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.J Clin Oncol,33,2660-2666.
  2. Antonia, SJ,Villegas, A,Daniel, D(2018).Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.N Engl J Med,379,2342-2350.
  3. Antonia, SJ,Villegas, A,Daniel, D(2017).Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.N Engl J Med,377,1919-1929.
  4. Auperin, A,Le Pechoux, C,Rolland, E(2010).Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.J Clin Oncol,28,2181-2190.
  5. Brahmer, J,Reckamp, KL,Baas, P(2015).Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.N Engl J Med,373,123-135.
  6. Chen, YM(2020).First-line combination immunotherapy for metastatic non-small cell lung cancer.JCMA,83,433-441.
  7. Faivre-Finn, C,Vicente, D,Kurata, T(2021).Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC - an update from the PACIFIC trial.J Thorac Oncol,16(5),860-867.
  8. Gadgeel, S,Rodriguez-Abreu, D,Speranza, G(2020).Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.J Clin Oncol,38,1505-1517.
  9. Gandhi, L,Rodriguez-Abreu, D,Gadgeel, S(2018).Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.N Engl J Med,378,2078-2092.
  10. Gravara, LD,Battiloro, C,Cantile, R(2020).Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?.Lung Cancer Manag,9,LMT22.
  11. Hanna, NH,Schneider, BJ,Temin, S(2020).Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.J Clin Oncol,38,1608-1632.
  12. Hellmann, MD,Paz-Ares, L,Bernabe Caro, R(2019).Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.N Engl J Med,381,2020-2031.
  13. Herbst, RS,Baas, P,Kim, DW(2016).Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.Lancet,387,1540-1550.
  14. Herbst, RS,Giaccone, G,de Marinis, F(2020).Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.N Engl J Med,383,1328-1339.
  15. Horn, L,Spigel, DR,Vokes, EE(2017).Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).J Clin Oncol,35,3924-3933.
  16. Hui, R,Ozguroglu, M,Villegas, A(2019).Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.Lancet Oncol,20,1670-1680.
  17. Murakami, S.(2019).Durvalumab for the treatment of non-small cell lung cancer.Expert Rev Anticancer Ther,19,1009-1016.
  18. Pai-Scherf, L,Blumenthal, GM,Li, H(2017).FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.Oncologist,22,1392-1399.
  19. Paz-Ares, L,Luft, A,Vicente, D(2018).Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.N Engl J Med,379,2040-2051.
  20. Quaglia, MG,Farina, A,Bossu, E(1998).Human alpha1-glycoprotein acid as chiral selector in the enantioseparation of midodrine and deglymidodrine racemates by HPLC.J Pharm Biomed Anal,18,171-177.
  21. Reck, M,Brahmer, J,Bennett, B(2018).Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.Eu J Cancer,102,23-30.
  22. Reck, M,Rodriguez-Abreu, D,Robinson, AG(2019).Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.J Clin Oncol,37,537-546.
  23. Reck, M,Rodriguez-Abreu, D,Robinson, AG(2016).Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.N Engl J Med,375,1823-1833.
  24. Rittmeyer, A,Barlesi, F,Waterkamp, D(2017).Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.Lancet,389,255-265.
  25. Socinski, MA,Jotte, RM,Cappuzzo, F(2018).Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.N Engl J Med,378,2288-2301.
  26. Vaddepally, RK,Kharel, P,Pandey, R(2020).Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence.Cancers,12,738.
  27. Vokes, EE,Ready, N,Felip, E(2018).Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.Annals of oncology : official journal of the European Society for Medical Oncology / ESMO,29,959-965.
被引用次数
  1. 黃秀霖,江珮蓁(2023)。照顧一位肺腺癌個案接受免疫治療引發相關皮膚副作用之護理經驗。志為護理-慈濟護理雜誌,22(3),118-125。